By Denny Jacob
Dermata Therapeutics received a newly issued patent in Japan. Shares more than doubled in after-market trading.
Applied Therapeutics said a trial of AT-001 failed to show a statistically significant difference between the treatment and placebo. Shares drop 30% in post-market trading.
Fusion Pharmaceuticals had a study protocol approved by regulators. Shares rise 7.7% in after-market trading.
Write to Denny Jacob at [email protected]
Read the full article here
